Claritev (CTEV) Stock Price, News & Analysis

Company Overview

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design. By focusing on purpose-built solutions that support all key players — including payors, employers, patients, providers and third parties — we aim to make healthcare more accessible and affordable for all. 

Key Stats

• Today's Range: $37.66 to $39.08
• 50-Day Range: $21.50 to $41.73
• 52-Week Range: $11.50 to $74.07
• Volume: 70,569 shs
• Average Volume: 128,707 shs
• Market Capitalization: $646.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.83
• Consensus Rating: Moderate Buy

Claritev Stock Analysis - MarketRank™

Claritev scored higher than 61% of companies evaluated by MarketBeat, and ranked 317th out of 910 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Claritev has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Claritev has a consensus price target of $44.83, representing about 17.5% upside from its current price of $38.16.

Amount of Analyst Coverage

Claritev has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Claritev are expected to grow in the coming year, from ($15.13) to ($13.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Claritev is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Claritev is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.88% of the float of Claritev has been sold short.

Short Interest Ratio / Days to Cover

Claritev has a short interest ratio ("days to cover") of 6.72.

Change versus previous month

Short interest in Claritev has recently increased by 0.01%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Claritev does not currently pay a dividend.

Dividend Growth

Claritev does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.41

News Sentiment

Claritev has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Claritev this week, compared to 3 articles on an average week.

Company Ownership

• Score: 3.1 / 5
• Insider Trading: Selling Shares

Cluster Insider Buying

2 insiders have purchased shares of Claritev in the last three months. Multiple insiders buying is a strong bullish signal.

Insider Buying vs. Insider Selling

In the past three months, Claritev insiders have sold 134.32% more of their company's stock than they have bought. Specifically, they have bought $274,540.00 in company stock and sold $643,297.00 in company stock.

Percentage Held by Insiders

7.40% of the stock of Claritev is held by insiders.

Percentage Held by Institutions

87.15% of the stock of Claritev is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/06/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Technology
• Sub-Industry: Healthcare Technology
• Current Symbol: NYSE:CTEV
• CIK: 1793229
• Web: www.claritev.com
• Phone: 1-800-677-1098
• Fax: N/A
• Employees: 3,000
• Year Founded: 1980

Price Target and Rating

• Average Price Target for Claritev: $44.83
• High Price Target: $73.00
• Low Price Target: $30.00
• Potential Upside/Downside: +17.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($17.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$284.28 million
• Net Margins: -28.46%
• Pretax Margin: -37.16%
• Return on Equity: N/A
• Return on Assets: -5.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.00
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $965.41 million
• Price / Sales: 0.67
• Cash Flow: $15.33 per share
• Price / Cash Flow: 2.49
• Book Value: ($10.10) per share
• Price / Book: -3.78

Miscellaneous

• Outstanding Shares: 16,950,000
• Free Float: 15,693,000
• Market Cap: $646.81 million
• Optionable: Optionable
• Beta: 0.88